Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - Asterias Biotherapeutics, Inc. | a50737782_ex99-1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): October
28, 2013
Asterias
Biotherapeutics, Inc.
(Exact name of registrant as
specified in its charter)
Delaware |
000-55046 |
46-1047971 |
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.)
|
230 Constitution Drive
Menlo
Park, California 94025
(Address
of principal executive offices)
(510)
521-3390
(Registrant's telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward-Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “may, “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in periodic reports filed by Asterias Biotherapeutics, Inc. with the Securities and Exchange Commission under the heading “Risk Factors” and other filings that Asterias may make with the Securities and Exchange Commission. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, Asterias disclaims any intent or obligation to update these forward-looking statements.
This Report and any accompanying exhibits shall be deemed “furnished” and not “filed” under the Securities Exchange Act of 1934, as amended.
Item 7.01 - Regulation FD Disclosure
On October 28, 2013, Asterias Biotherapeutics, Inc. issued the press release furnished as Exhibit 99.1, which is incorporated by reference.
Section 9-Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
Exhibit Number |
Description |
99.1 | Press Release Dated October 28, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ASTERIAS BIOTHERAPEUTICS, INC. | ||
Date: October 28, 2013 | By |
/s/ Thomas Okarma |
Chief Executive Officer |
Exhibit Number | Description |
99.1 | Press Release Dated October 28, 2013 |